Cell And Gene Therapy Manufacturing Market
Report ID: SQMIG35J2370
Report ID: SQMIG35J2370
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2370 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
115
|Figures:
77
Global Cell And Gene Therapy Manufacturing Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.76 Billion in 2025 to USD 28.85 Billion by 2033, growing at a CAGR of 14.52% during the forecast period (2026-2033).
The cell and gene therapy manufacturing market has changed considerably over the past decade due to the interplay between scientific advancements and unmet clinical requirements. As such, the biomanufacturing marketplace is now defined by GMP biomanufacturing processes developed for autologous and allogeneic cell therapies, viral vector and genome-edited products, which are designed to provide durable, single-administration therapies for patients with cancer and/or rare genetic disorders. There has been a progression from academic laboratories to GMP contract manufacturers to develop CAR T-cell therapies that transitioned from single center proof of concept to multiple location production. Similarly, adeno-associated virus vectors progressed from small trials aimed at treating a select group of patients to programs aimed at treating large population requiring significant amounts of resources for research and testing.
To keep pace with the explosive demand for viral vectors and the continuing complexity of individualized patient-specific workflows for CAR T-cell therapy, sponsors are increasingly using CDMOs (contract development and manufacturing organizations) and modular single-use facilities to increase throughput and reduce risk of contamination in their manufacturing operations. When regulators develop clearer guidance around potency and comparability of product, manufacturers invest in processes and systems to automate their operations and utilize advanced analytic tools to improve yield and consistency of their products. The improved operational efficiencies afforded through development of AAV and CAR T therapies have resulted in the ability to conduct more global clinical trials and have expanded indications for patients haves.
How is AI transforming quality control in cell and gene therapy manufacturing?
AI technology is having a huge impact on quality control in cell and gene therapy manufacturing through improved data capture combined with advanced machine learning models. These new models allow for continuous monitoring of various attributes for every product produced. AI has provided the ability for automated image analysis to verify cultured cells, rapid integration of numerous sensor-based data streams to detect out-of-norm results, and predictive AI models which allow manufacturers to proactively identify trends that would ultimately lead to product batch failures. This combination of data analytics and human expertise now creates a hybrid work flow between these two areas to greatly increase the speed of release testing, reduce variability in manual operation, support reliable manufacturing at scale and satisfy the increasing regulatory requirement of quality. Specific real world examples of this are the implementation of AI guided microscopy for verifying cell viability and AI models that assist manufacturers in streamlining release assays and characterizing their products analytically.
In February 2026, Cellares announced the expansion of its Cell Q automated in process and release quality control systems (AI-optimized) to verify and document the quality of gene edited stem cell therapies through AI powered technologies that are designed to improve quality by eliminating hands on variability, shortening release times to aid manufacturers when producing scaled volumes while meeting the demands of an evolving market.
Market snapshot - (2026-2033)
Global Market Size
USD 8.52 Billion
Largest Segment
Cell Therapy Manufacturing
Fastest Growth
Gene Therapy Manufacturing
Growth Rate
14.52% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global cell and gene therapy manufacturing market is segmented by therapy type, process, scale, end-user and region. Based on therapy type, the market is segmented into Cell Therapy Manufacturing and Gene Therapy Manufacturing. Based on process, the market is segmented into Upstream Bioprocessing, Downstream Purification and Fill-Finish. Based on scale, the market is segmented into Clinical-Scale and Commercial-Scale. Based on end-user, the market is segmented into Pharma & Biotech Companies, CDMOs and Academic Medical Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Upstream bioprocessing segment dominates with cell and gene therapy manufacturing market share because it controls the critical determinants of yield, potency and reproducibility early in the production chain, shaping downstream requirements and regulatory outcomes. Advances in platform cell lines, media optimization and intensified bioreactor strategies reduce variability and lower unit cost, enabling predictable tech transfer and streamlined scale transitions that buyers and regulators view as fundamental to commercial viability.
As per cell and gene therapy manufacturing market outlook, downstream purification is emerging as the most rapidly expanding area as demand for high purity viral vectors and engineered cells drives innovation in chromatography media, single use flow paths and continuous capture approaches. Regulatory focus on impurity profiles and faster release expectations accelerates investment in novel purification technologies, creating new supplier niches and service models that expand manufacturing capacity and quality control capabilities.
As per cell and gene therapy manufacturing market forecast, CDMOs segment leads because they aggregate specialized facilities, cross project operational knowledge and regulatory experience that many sponsors lack, providing a pragmatic path from development to commercial supply. Their investments in flexible platforms and quality systems lower developer capital burden, enable rapid scale transitions and concentrate scarce technical expertise, which in turn encourages more sponsors to outsource complex manufacturing tasks to mitigate risk.
As per cell and gene therapy manufacturing market analysis, pharma & biotech companies segment is the fastest growing manufacturing cohort as sponsors internalize production to protect IP, control critical quality attributes and shorten clinical timelines. Strategic investments in in house platforms, tech transfer capabilities and modular facilities increase manufacturing autonomy, driving demand for specialized equipment, talent and new collaborations that redefine market opportunity and supplier strategies.
To get detailed segments analysis, Request a Free Sample Report
As per cell and gene therapy manufacturing market regional forecast, North America dominance, supported by an integrated ecosystem that brings together advanced industrial infrastructure, strong scientific expertise, and a mature regulatory framework. The concentration of major biopharma enterprises and specialized contract development and manufacturing teams facilitates rapid scale up and technology transfer. Strong translational research is producing a strong pipeline of complicated medicines emerging from academic institutes and into commercial manufacture. Coordinated supply chain networks and set quality standards minimize time to market and de-risk commercialization, further cementing the region as the chosen place for high complexity cell and gene therapy manufacturing. Close collaboration between regulators, industry and payers facilitates predictable development pathways and commercialization strategies. A mature manufacturing team trained in complicated biologics and gene editing methods speeds the transition from bench to production.
As per cell and gene therapy manufacturing market regional outlook, U.S. is the hub of a cluster of premier biotechnology businesses, advanced contract development and manufacturing organizations, and prolific translational research from academic centers. Existing regulatory relationships and plentiful private capital enable fast facility build and process optimization. The ecosystem centers on automation, quality by design and specialized expertise, creating an environment in which complicated medicines are moved quickly from research to commercial production and clinical application.
Canada exhibits a growing network of biomanufacturing centres and contract providers that complement neighbouring markets. Supportive public policy and collaborative research institutions foster translation of innovative therapies into scalable processes. Emphasis on niche capabilities, workforce training, and quality management helps attract partnerships with global developers seeking capacity. Focused efforts on supply chain resilience and regulatory alignment further strengthen Canada role within regional manufacturing ecosystem.
As per cell and gene therapy manufacturing industry analysis, the quick growth in Europe is due to a combination of national strategies, focused scientific brilliance and a growing network of specialized manufacturing suppliers. Strong university hospitals and translational centers are creating a growing pipeline that offers incentives for investment in more sophisticated facilities and process innovation. Harmonizing regulatory procedures and increasing the engagement between industry and health authorities encourage clearer paths from clinical development to commercial manufacturing. Strategic alliances between established pharmaceutical companies and nimble biotechnology firms speed up technology transfer and capacity build up. Public funding initiatives and regional clusters are also helping to boost workforce development and infrastructure expansion, while quality and compliance remain the backbone of European competitiveness in sophisticated cell and gene therapy production. Deep engineering talent and specialist equipment suppliers are located at prime production centers in the central and western areas. Cross border partnerships and a rising contract manufacturing industry provide flexible production models to address the different needs of national healthcare systems.
Germany has the combination of engineering excellence and an industrial basis to facilitate high grade bioproduction. robust capabilities are built on a robust manufacturing infrastructure, development teams and good relationships between research institutions and industry. Due to the emphasis on precision production, automation and quality requirements, partnerships are formed for complicated operations. The regional clusters supply specialized suppliers and qualified labor, enabling Germany to operate as a primary manufacturing base within Europe for cell and gene therapies.
United Kingdom demonstrates growth driven by agile regulatory approaches, strong translational research networks, and collaboration between universities and industry. A supportive innovation ecosystem encourages spinouts and partnerships that accelerate manufacturing scale. Healthcare delivery perspectives inform commercial strategy and adoption pathways. Investment in specialized facilities, workforce training, and technology transfer capabilities position United Kingdom as an environment for commercializing complex cell and gene therapies.
France is emerging through coordinated national initiatives, expanding bioproduction platforms, and public investment. Strengthening links between research hospitals and manufacturing centres supports translation of academic innovations into scalable processes. Emphasis on workforce development, regulatory alignment, and regional partnerships attracts domestic and international collaboration. Growing contract manufacturing capabilities and specialized facilities enable France to develop focused strengths in therapeutic modalities and contribute to European manufacturing.
Asia Pacific region is establishing its position by using strategic public investment, swift capacity building and targeted talent development to facilitate the production of sophisticated cell and gene therapies. Governments and private investors are facilitating the building of advanced bioproduction facilities, and supporting technology transfer from worldwide partners. Enhanced regulatory processes and more corporate involvement with health authorities are offering more transparent approval and manufacturing approaches. Cost competitive manufacturing advantages and growing adoption of automation and digital process controls is a boon for the region. The growth of contract manufacturing networks and international collaborations will help scale and improve quality, while a maturing foundation of research institutions provides creative pipelines for industrialisation in many Asia Pacific markets. Emphasize innovative bioprocess technology and workforce development in key markets to improve quality and regulatory alignment. Asia Pacific is being positioned as a significant source of high quality manufacturing capacity through cross border alliances and export tactics.
Japan is advancing through investments in automation, precision bioprocessing, and analytics integration into production workflows. Established pharmaceutical and medtech sectors transfer manufacturing expertise into cell and gene therapy platforms. Collaboration between regulators and industry refines pathways for clinical translation and commercial supply. Emphasis on quality systems, equipment supply, and skilled workforce positions Japan as a source of technologically advanced manufacturing capacity in the region.
South Korea is building manufacturing capabilities through investment in bioprocessing infrastructure, contract development and manufacturing, and workforce training. A vibrant biotech industry and export strategy attract partnerships and technology transfer. Regulatory modernization and incentives for clinical manufacturing support translation of therapies into supply. Emphasis on process innovation, automation, and quality control positions South Korea as a competitive, high quality manufacturing hub within Asia Pacific.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advances In Bioprocess Technologies
Increasing Regulatory Support For Therapies
High Manufacturing Costs Persist
Supply Chain Vulnerabilities
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in global cell and gene therapy manufacturing industry is shaped by consolidation and platform differentiation, driven by demand for scalable viral vector and automated cell production capacity. Firms pursue M&A to secure vector capacity, exemplified by Ajinomoto's acquisition of Forge Biologics. Strategic partnerships and tech innovation like Bristol Myers Squibb's alliance with Cellares and Cellares' automated Cell Shuttle further intensify competition.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global cell and gene therapy manufacturing market growth is driven primarily by the convergence of scientific breakthroughs and unmet clinical needs that move therapies from research into GMP production, supported also by rapid advances in bioprocess technologies that improve scalability and consistency. Growth is constrained by persistently high manufacturing costs associated with specialized facilities, equipment and skilled personnel. North America remains the dominant region due to deep scientific talent, regulatory maturity and concentrated CDMO capacity, while upstream bioprocessing leads the market by controlling yield, potency and reproducibility early in production. These dynamics favor modular facilities, automation and strategic outsourcing to reduce time to market and unit cost.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 8.52 Billion |
| Market size value in 2033 | USD 28.85 Billion |
| Growth Rate | 14.52% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Cell And Gene Therapy Manufacturing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cell And Gene Therapy Manufacturing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cell And Gene Therapy Manufacturing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cell And Gene Therapy Manufacturing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Cell And Gene Therapy Manufacturing Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.76 Billion in 2025 to USD 28.85 Billion by 2033, growing at a CAGR of 14.52% during the forecast period (2026-2033).
Competitive landscape in global cell and gene therapy manufacturing is shaped by consolidation and platform differentiation, driven by demand for scalable viral vector and automated cell production capacity. Firms pursue M&A to secure vector capacity, exemplified by Ajinomoto's acquisition of Forge Biologics. Strategic partnerships and tech innovation like Bristol Myers Squibb's alliance with Cellares and Cellares' automated Cell Shuttle further intensify competition. 'Lonza Group (Cocoon Platform)', 'Catalent Inc.', 'Thermo Fisher Scientific', 'WuXi Advanced Therapies', 'Fujifilm Diosynth Biotechnologies', 'Sartorius AG', 'Cytiva (Danaher)', 'Oxford Biomedica plc', 'Andelyn Biosciences', 'Cellipont Bioservices', 'PCT (Hitachi)', 'Novatek International', 'AGC Biologics', 'Orion Pharma', 'Kite Pharma (Gilead)', 'Novartis (AveXis)', 'Bristol Myers Squibb (Juno)', 'Samsung Biologics', 'Rentschler Biopharma', 'KBI Biopharma'
Rapid advances in bioprocess technologies enhance scalability, consistency, and throughput for cell and gene therapy manufacturing, enabling developers to move products from lab scale toward commercial production more efficiently. Improved bioreactor designs, automation of cell handling, and refined process controls reduce variability and increase batch reliability, which supports broader adoption by contract manufacturers and innovators. These technical improvements lower operational complexity and help align manufacturing capability with clinical demand, fostering investment in capacity expansion and encouraging companies to pursue more ambitious therapeutic programs that depend on dependable, reproducible production.
Modular Facility Expansion: Adoption of modular, prefabricated facility designs accelerates deployment of production capacity and enables rapid reconfiguration for diverse cell and gene therapies. Flexible cleanroom modules and single-use systems reduce lead times and support regionalized manufacturing models, allowing developers to prioritize clinical agility. This trend fosters collaboration between sponsors and specialized contract manufacturers, promotes plug-and-play process integration, and mitigates technology obsolescence by simplifying retrofits. Investors and regulators increasingly favor modular approaches for validation pathways and scalable capacity aligned with evolving therapeutic pipelines.
Why does North America Dominate the Global Cell And Gene Therapy Manufacturing Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
